As we all know, there are many different methods for the synthesis of a compound, and people can choose the synthesis method that suits their own laboratory according to the actual situation. 355806-00-7, name is (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester, molecular formula is C26H36FN3O6S, The compound is widely used in many fields, so it is necessary to find a new synthetic route. The downstream synthesis method of this compound is introduced below. name: (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester
Example 7- (Preparation in ACN/H20) A 250ML flask equipped with a mechanical stirrer was charged with ACN (25 mL), t- Butyl-Rosuvastatin (5 g), H20 (25 mL) and NAOH pellets (1. 86G). The mixture was stirred at ambient temperature for 2 hours. The phases were separated in a separating funnel. The aqueous phase was concentrated under reduced pressure to obtain an oily residue (12.0 g). To this residue was added water (40 ml) and 5.5 g CaCl2. The solution was stirred at ambient temperature for 15 hours (overnight) to form a white precipitate. The organic phase was concentrated under reduced pressure to obtain an oily residue (13.0 g). To this residue were added 40 mL water and 5.5 g CaCl2. The solution was stirred at ambient temperature for 15 hours (over night) to FORM a white precipitate. Both parts were filtered and washed with 10 mL of water to get a powdery compound. (0. 86 g from aqueous phase, 4.01 g from organic phase)
With the rapid development of chemical substances, we look forward to future research findings about 355806-00-7.
Reference:
Patent; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.; WO2005/23778; (2005); A2;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia